Pzena Investment Management MRK trades
Richard Pzena
Richard Pzena Merck & Company Inc stake
total: 590
Trades details
- Total transactions:
- 30
- New positions:
- 4
- Sold out:
- 4
- Added:
- 6
- Reduced:
- 16
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q3
According to 2026 Q3 report, Richard Pzena doesn't hold any Merck & Company Inc (MRK) shares. To date, the estimated cost basis is nearly $79.16 for "buy" trades and estimated average "sell" price is $126.49. Pzena Investment Management first purchased MRK in 2016 Q1, initially acquiring 921,365 shares. Richard Pzena later completely sold out the position and invested in Merck & Company Inc again in 2025 Q2. Since the initial investment in Merck & Company Inc (MRK), Pzena Investment Management has made 29 more transactions.
When did Richard Pzena sell Merck & Company Inc (MRK)?
Richard Pzena sold off the entire Merck & Company Inc (MRK) position in 2026 Q3.
When did Richard Pzena buy Merck & Company Inc (MRK)?
Richard Pzena first invested in Merck & Company Inc (MRK) in 2016 Q1 at the reported quarter-end price of $52.91 per share.
What's the cost basis of Pzena Investment Management's MRK stake?
The estimated cost basis for Merck & Company Inc (MRK) stake is around $79.16 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $79.16
- Weighted AVG sell price:
- $126.49
Richard Pzena's historical trades in Merck & Company Inc
30 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q3
|
0.00%
|
0
|
$128.50
|
|
-100% (-2,511)
|
-0%
|
|
2026 Q1
|
0.00%
|
2,511
|
$120.29
|
$302,048
|
-24.46% (-813)
|
-0%
|
|
2025 Q2
|
0.00%
|
3,324
|
$79.16
|
$263,128
|
new
|
+0%
|
|
2025 Q1
|
0.00%
|
0
|
$99.48
|
|
-100% (-2,898)
|
-0%
|
|
2024 Q4
|
0.00%
|
2,898
|
$99.48
|
$288,293
|
new
|
+0%
|
|
2022 Q4
|
0.00%
|
0
|
$86.07
|
|
-100% (-6,425)
|
-0%
|
|
2022 Q3
|
0.00%
|
6,425
|
$86.07
|
$553,000
|
-9.95% (-710)
|
-0%
|
|
2022 Q2
|
0.00%
|
7,135
|
$91.10
|
$650,000
|
+40.12% (+2,043)
|
+0%
|
|
2022 Q1
|
0.00%
|
5,092
|
$82.09
|
$418,000
|
-26.04% (-1,793)
|
-0%
|
|
2021 Q4
|
0.00%
|
6,885
|
$76.69
|
$528,000
|
-9.63% (-734)
|
-0%
|
|
2021 Q2
|
0.00%
|
$77.83
|
-10.85% (-927)
|
|||
|
2021 Q1
|
0.00%
|
$77.11
|
new
|
|||
|
2020 Q2
|
0.00%
|
$76.96
|
-100% (-25,598)
|
|||
|
2020 Q1
|
0.01%
|
$76.96
|
-56.47% (-33,213)
|
|||
|
2019 Q4
|
0.02%
|
$90.95
|
-92.36% (-710,611)
|
|||
|
2019 Q3
|
0.35%
|
$84.18
|
-39.09% (-493,812)
|
|||
|
2019 Q2
|
0.56%
|
$83.85
|
-33.90% (-647,822)
|
|||
|
2019 Q1
|
0.86%
|
$83.17
|
-48.08% (-1,769,911)
|
|||
|
2018 Q4
|
1.64%
|
$76.41
|
-23.60% (-1,136,793)
|
|||
|
2018 Q3
|
1.66%
|
$70.94
|
-1.77% (-86,576)
|
|||
|
2018 Q2
|
1.50%
|
$60.70
|
+8.40% (+379,906)
|
|||
|
2018 Q1
|
1.25%
|
$54.47
|
+175.79% (+2,883,906)
|
|||
|
2017 Q4
|
0.45%
|
$56.27
|
+7.93% (+120,565)
|
|||
|
2017 Q3
|
0.51%
|
$64.03
|
+84.25% (+695,019)
|
|||
|
2017 Q2
|
0.29%
|
$64.09
|
-0.16% (-1,293)
|
|||
|
2017 Q1
|
0.30%
|
$63.54
|
-34.47% (-434,620)
|
|||
|
2016 Q4
|
0.42%
|
$58.87
|
-10.49% (-147,825)
|
|||
|
2016 Q3
|
0.54%
|
$62.41
|
-0.47% (-6,712)
|
|||
|
2016 Q2
|
0.51%
|
$57.61
|
+53.62% (+494,025)
|
|||
|
2016 Q1
|
0.30%
|
$52.91
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.